| Primary |
| Suicide Attempt |
80.0% |
| Major Depression |
20.0% |
|
| Drug Exposure During Pregnancy |
33.3% |
| Sopor |
33.3% |
| Suicide Attempt |
33.3% |
|
| Secondary |
| Product Used For Unknown Indication |
42.4% |
| Drug Use For Unknown Indication |
18.1% |
| Depression |
7.8% |
| Anxiety |
4.1% |
| Bipolar I Disorder |
3.3% |
| Hiv Infection |
2.9% |
| Schizoaffective Disorder |
2.9% |
| Pain |
2.2% |
| Suicide Attempt |
2.2% |
| Abnormal Behaviour |
2.1% |
| Hypertension |
1.7% |
| Multiple Sclerosis |
1.7% |
| Drug Exposure During Pregnancy |
1.3% |
| Maternal Exposure During Pregnancy |
1.3% |
| Toxicity To Various Agents |
1.3% |
| Insomnia |
1.1% |
| Crohn's Disease |
1.0% |
| Intentional Overdose |
1.0% |
| Maternal Exposure Timing Unspecified |
1.0% |
| Nausea |
0.8% |
|
| Cytolytic Hepatitis |
10.8% |
| Suicide Attempt |
9.8% |
| Transaminases Increased |
9.8% |
| Sudden Death |
8.8% |
| Somnolence |
7.8% |
| Hepatitis |
4.9% |
| Drug Exposure During Pregnancy |
3.9% |
| Dyspnoea Exertional |
3.9% |
| Hyponatraemia |
3.9% |
| Hypothermia |
3.9% |
| Pulmonary Arterial Hypertension |
3.9% |
| Respiratory Acidosis |
3.9% |
| Urinary Tract Infection |
3.9% |
| Visual Acuity Reduced |
3.9% |
| Extrapyramidal Disorder |
2.9% |
| Hiccups |
2.9% |
| Overdose |
2.9% |
| Premature Baby |
2.9% |
| Weight Decreased |
2.9% |
| Blood Ph Increased |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
28.6% |
| Product Used For Unknown Indication |
12.7% |
| Depression |
12.3% |
| Anxiety |
10.6% |
| Hypertension |
6.0% |
| Pain |
2.9% |
| Insomnia |
2.7% |
| Type 2 Diabetes Mellitus |
2.5% |
| Breast Cancer |
2.4% |
| Parkinson's Disease |
2.3% |
| Asthma |
2.3% |
| Ill-defined Disorder |
2.1% |
| Hepatitis C |
2.0% |
| Hiv Infection |
1.9% |
| Non-small Cell Lung Cancer |
1.8% |
| Major Depression |
1.5% |
| Rheumatoid Arthritis |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Smoking Cessation Therapy |
1.3% |
| Dyslipidaemia |
1.2% |
|
| Vomiting |
8.3% |
| Suicide Attempt |
7.1% |
| Condition Aggravated |
5.8% |
| Hyponatraemia |
5.8% |
| Syncope |
5.8% |
| Vertigo |
5.8% |
| Psychotic Disorder |
5.1% |
| Pyrexia |
5.1% |
| Weight Decreased |
5.1% |
| Weight Increased |
5.1% |
| Leukopenia |
4.5% |
| Tachycardia |
4.5% |
| Toxic Skin Eruption |
4.5% |
| Urinary Retention |
4.5% |
| Hepatocellular Injury |
3.8% |
| Jaundice |
3.8% |
| Lung Disorder |
3.8% |
| Myocardial Infarction |
3.8% |
| Neutropenia |
3.8% |
| Paraesthesia |
3.8% |
|
| Interacting |
| Product Used For Unknown Indication |
100.0% |
|
| Somnolence |
50.0% |
| Toxicity To Various Agents |
50.0% |
|
